{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:45:33Z","timestamp":1790279133690,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["19661"],"award-info":[{"award-number":["19661"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["19661"],"award-info":[{"award-number":["19661"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A31287"],"award-info":[{"award-number":["A31287"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["19661"],"award-info":[{"award-number":["19661"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A29799"],"award-info":[{"award-number":["A29799"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["19661"],"award-info":[{"award-number":["19661"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF#18CHAL11"],"award-info":[{"award-number":["PCF#18CHAL11"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF#18CHAL11"],"award-info":[{"award-number":["PCF#18CHAL11"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF#18CHAL11"],"award-info":[{"award-number":["PCF#18CHAL11"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PC) is the commonest male visceral cancer, and second leading cause of cancer mortality in men in the Western world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using a forward-mutagenesis Sleeping Beauty (SB) transposon-based screen in a Probasin Cre-Recombinase (\n                      <jats:italic>Pb-Cre<\/jats:italic>\n                      )\n                      <jats:italic>Pten<\/jats:italic>\n                      -deficient mouse model of PC, we identified\n                      <jats:italic>Arid1a<\/jats:italic>\n                      loss as a driver in the development of metastatic disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The insertion of transposon in the\n                      <jats:italic>Arid1a<\/jats:italic>\n                      gene resulted in a 60% reduction of\n                      <jats:italic>Arid1a<\/jats:italic>\n                      expression, and reduced tumour free survival (\n                      <jats:italic>SB:Pten<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      <jats:italic>Arid1a<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>INT<\/jats:italic>\n                      <\/jats:sup>\n                      median 226 days vs\n                      <jats:italic>SB:Pten<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      <jats:italic>Arid1a<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>WT<\/jats:italic>\n                      <\/jats:sup>\n                      293 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02),with elevated rates of metastasis (\n                      <jats:italic>SB:Pten<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      <jats:italic>Arid1a<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>INT<\/jats:italic>\n                      <\/jats:sup>\n                      75% lung metastasis rate vs 17%\n                      <jats:italic>SB:Pten<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      <jats:italic>Arid1a<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>WT<\/jats:italic>\n                      <\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). We further generated a\n                      <jats:italic>Pb-Cre Pten<\/jats:italic>\n                      - and\n                      <jats:italic>Arid1a<\/jats:italic>\n                      -deficient mouse model, in which loss of\n                      <jats:italic>Arid1a<\/jats:italic>\n                      demonstrated a profound acceleration in tumorigenesis in\n                      <jats:italic>Pten<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      mice compared to\n                      <jats:italic>Pten<\/jats:italic>\n                      loss alone (\n                      <jats:italic>Pb-Cre Pten<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      <jats:italic>Arid1a<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>+\/+<\/jats:italic>\n                      <\/jats:sup>\n                      median survival of 267 days vs Pb-Cre\n                      <jats:italic>Pten<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      <jats:italic>Arid1a<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>fl\/fl<\/jats:italic>\n                      <\/jats:sup>\n                      103 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our data revealed homozygous\n                      <jats:italic>Arid1a<\/jats:italic>\n                      loss is required to dramatically accelerate prostate tumourigenesis. Analysis of RNA and ChIP -Sequencing data suggests\n                      <jats:italic>Arid1a<\/jats:italic>\n                      loss enhanced the function of AP-1 subunit cFos. In clinical PC cohort, ARID1A and cFos levels stratified an aggressive subset of PC with a poor survival outcome with a median of only 30 months.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-02944-3","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:32:39Z","timestamp":1738240359000},"page":"502-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos"],"prefix":"10.1038","volume":"132","author":[{"given":"Andrew","family":"Hartley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C. A.","family":"Galbraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Veeratterapillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9304-439X","authenticated-orcid":false,"given":"Karen","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-1926","authenticated-orcid":false,"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2944_CR1","unstructured":"UK CR. Prostate Cancer Statistics https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer."},{"key":"2944_CR2","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.1073\/pnas.1601571113","volume":"113","author":"I Ahmad","year":"2016","unstructured":"Ahmad I, Mui E, Galbraith L, Patel R, Tan EH, Salji M, et al. Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proc Natl Acad Sci. 2016;113:8290.","journal-title":"Proc Natl Acad Sci"},{"key":"2944_CR3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/s41416-023-02237-7","volume":"128","author":"AJ Tibbo","year":"2023","unstructured":"Tibbo AJ, Hartley A, Vasan R, Shaw R, Galbraith L, Mui E, et al. MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer. Br J Cancer. 2023;128:1991\u20139.","journal-title":"Br J Cancer"},{"key":"2944_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pbiomolbio.2010.05.001","volume":"102","author":"L Tang","year":"2010","unstructured":"Tang L, Nogales E, Ciferri C. Structure and function of SWI\/SNF chromatin remodeling complexes and mechanistic implications for transcription. Prog Biophys Mol Biol. 2010;102:122\u20138.","journal-title":"Prog Biophys Mol Biol"},{"key":"2944_CR5","doi-asserted-by":"crossref","unstructured":"Yegnasubramanian S, De Marzo AM, Nelson WG. Prostate cancer epigenetics: from basic mechanisms to clinical implications. Cold Spring Harb Perspect Med. 2019;1:9.","DOI":"10.1101\/cshperspect.a030445"},{"key":"2944_CR6","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1074\/jbc.M808782200","volume":"284","author":"S Flowers","year":"2009","unstructured":"Flowers S, Nagl NG Jr., Beck GR Jr., Moran E. Antagonistic roles for BRM and BRG1 SWI\/SNF complexes in differentiation. J Biol Chem. 2009;284:10067\u201375.","journal-title":"J Biol Chem"},{"key":"2944_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","volume":"3","author":"JN Wu","year":"2013","unstructured":"Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3:35\u201343.","journal-title":"Cancer Discov"},{"key":"2944_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4161\/cbt.28411","volume":"15","author":"RC Wu","year":"2014","unstructured":"Wu RC, Wang TL, Shih Ie M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15:655\u201364.","journal-title":"Cancer Biol Ther"},{"key":"2944_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0690-5","volume":"11","author":"M Sen","year":"2019","unstructured":"Sen M, Wang X, Hamdan FH, Rapp J, Eggert J, Kosinsky RL, et al. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells. Clin Epigenetics. 2019;11:92.","journal-title":"Clin Epigenetics"},{"key":"2944_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","volume":"52","author":"G Xu","year":"2020","unstructured":"Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet. 2020;52:198\u2013207.","journal-title":"Nat Genet"},{"key":"2944_CR11","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1073\/pnas.1804858116","volume":"116","author":"Y Hiramatsu","year":"2019","unstructured":"Hiramatsu Y, Fukuda A, Ogawa S, Goto N, Ikuta K, Tsuda M, et al. Arid1a is essential for intestinal stem cells through Sox9 regulation. Proc Natl Acad Sci. 2019;116:1704\u201313.","journal-title":"Proc Natl Acad Sci"},{"key":"2944_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05694-4","volume":"9","author":"C Wu","year":"2018","unstructured":"Wu C, Lyu J, Yang EJ, Liu Y, Zhang B, Shim JS. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun. 2018;9:3212.","journal-title":"Nat Commun"},{"key":"2944_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5:752\u201367.","journal-title":"Cancer Discov"},{"key":"2944_CR14","doi-asserted-by":"crossref","unstructured":"Park Y, Chui MH, Suryo Rahmanto Y, Yu Z-C, Shamanna RA, Bellani MA, et al. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. Clin Cancer Res. 2019;25:5584\u201394.","DOI":"10.1158\/1078-0432.CCR-18-4222"},{"key":"2944_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/science.1196333","volume":"330","author":"S Jones","year":"2010","unstructured":"Jones S, Wang T-L, Shih I-M, Mao T-L, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene <em>ARID1A<\/em> in ovarian clear cell carcinoma. Science 2010;330:228\u201331.","journal-title":"Science"},{"key":"2944_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.molcel.2018.06.040","volume":"71","author":"GJ Sandoval","year":"2018","unstructured":"Sandoval GJ, Pulice JL, Pakula H, Schenone M, Takeda DY, Pop M, et al. Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis. Mol cell. 2018;71:554\u201366.e7.","journal-title":"Mol cell"},{"key":"2944_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110534","volume":"38","author":"CR Dufour","year":"2022","unstructured":"Dufour CR, Scholtes C, Yan M, Chen Y, Han L, Li T, et al. The mTOR chromatin-bound interactome in prostate cancer. Cell Rep. 2022;38:110534.","journal-title":"Cell Rep."},{"key":"2944_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","volume":"101","author":"X Wu","year":"2001","unstructured":"Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001;101:61\u20139.","journal-title":"Mech Dev"},{"key":"2944_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S1074-7613(01)00134-0","volume":"14","author":"A Suzuki","year":"2001","unstructured":"Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001;14:523\u201334.","journal-title":"Immunity"},{"key":"2944_CR20","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/ng.990","volume":"43","author":"HN March","year":"2011","unstructured":"March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, et al. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet. 2011;43:1202\u20139.","journal-title":"Nat Genet"},{"key":"2944_CR21","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1073\/pnas.0801802105","volume":"105","author":"X Gao","year":"2008","unstructured":"Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z. ES cell pluripotency and germ-layer formation require the SWI\/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci USA. 2008;105:6656\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2944_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.7","volume":"2","author":"I Ahmad","year":"2011","unstructured":"Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, et al. Ras mutation cooperates with \u03b2-catenin activation to drive bladder tumourigenesis. Cell Death Dis. 2011;2:e124.","journal-title":"Cell Death Dis"},{"key":"2944_CR23","unstructured":"Bioinformatics ASB FastQC. A quality control tool for high throughput sequence data Available from: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc."},{"key":"2944_CR24","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884\u2013i90.","journal-title":"Bioinformatics"},{"key":"2944_CR25","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.12688\/f1000research.15931.1","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett SW, Andrews S. FastQ Screen: A tool for multi-genome mapping and quality control. F1000Res. 2018;7:1338.","journal-title":"F1000Res"},{"key":"2944_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907\u201315.","journal-title":"Nat Biotechnol"},{"key":"2944_CR27","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence Alignment\/Map format and SAMtools. Bioinformatics. 2009;25:2078\u20139.","journal-title":"Bioinformatics"},{"key":"2944_CR28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"2944_CR29","unstructured":"Team RC. R: A Language and Environment for Statistical Computing Available from: https:\/\/www.R-project.org\/."},{"key":"2944_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nmeth.3252","volume":"12","author":"W Huber","year":"2015","unstructured":"Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12:115\u201321.","journal-title":"Nat Methods"},{"key":"2944_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"2944_CR32","first-page":"275","volume":"18","author":"M Stephens","year":"2017","unstructured":"Stephens M. False discovery rates: a new deal. Biostatistics. 2017;18:275\u201394.","journal-title":"Biostatistics"},{"key":"2944_CR33","doi-asserted-by":"publisher","first-page":"D745","DOI":"10.1093\/nar\/gky1113","volume":"47","author":"F Cunningham","year":"2019","unstructured":"Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, et al. Ensembl 2019. Nucleic Acids Res. 2019;47:D745\u2013d51.","journal-title":"Nucleic Acids Res"},{"key":"2944_CR34","doi-asserted-by":"publisher","first-page":"D884","DOI":"10.1093\/nar\/gkaa942","volume":"49","author":"KL Howe","year":"2021","unstructured":"Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, et al. Ensembl 2021. Nucleic Acids Res. 2021;49:D884\u2013d91.","journal-title":"Nucleic Acids Res"},{"key":"2944_CR35","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47:W191\u2013W8.","journal-title":"Nucleic Acids Res"},{"key":"2944_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2944_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138.","journal-title":"Nat Biotechnol"},{"key":"2944_CR38","doi-asserted-by":"crossref","first-page":"D87","DOI":"10.1093\/nar\/gkaa516","volume":"48","author":"O Fornes","year":"2020","unstructured":"Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48:D87\u2013d92.","journal-title":"Nucleic Acids Res"},{"key":"2944_CR39","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841\u20132.","journal-title":"Bioinformatics"},{"key":"2944_CR40","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1093\/bioinformatics\/bty194","volume":"34","author":"Z Wang","year":"2018","unstructured":"Wang Z, Civelek M, Miller CL, Sheffield NC, Guertin MJ, Zang C. BART: a transcription factor prediction tool with query gene sets or epigenomic profiles. Bioinformatics. 2018;34:2867\u20139.","journal-title":"Bioinformatics"},{"key":"2944_CR41","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan L, Fran\u00e7ois R, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4:1686.","journal-title":"J Open Source Softw"},{"key":"2944_CR42","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels P, Magnusson M, Lundin S, K\u00e4ller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32:3047\u20138.","journal-title":"Bioinformatics"},{"key":"2944_CR43","unstructured":"T. K. Jupyter Notebooks\u2014a publishing format for reproducible computational workflows IOS Press. 2016."},{"key":"2944_CR44","unstructured":"Team R. Rstudio: Integrated Development Environment for R 2019."},{"key":"2944_CR45","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1158\/0008-5472.CAN-19-3870","volume":"80","author":"N Rooney","year":"2020","unstructured":"Rooney N, Mason SM, McDonald L, D\u00e4britz JHM, Campbell KJ, Hedley A, et al. RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Res. 2020;80:2325\u201339.","journal-title":"Cancer Res"},{"key":"2944_CR46","doi-asserted-by":"publisher","first-page":"16392","DOI":"10.1073\/pnas.1101263108","volume":"108","author":"I Ahmad","year":"2011","unstructured":"Ahmad I, Patel R, Singh LB, Nixon C, Seywright M, Barnetson RJ, et al. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci USA. 2011;108:16392\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2944_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4:209\u201321.","journal-title":"Cancer Cell"},{"key":"2944_CR48","doi-asserted-by":"publisher","first-page":"e1005748","DOI":"10.1371\/journal.pgen.1005748","volume":"11","author":"JR Raab","year":"2016","unstructured":"Raab JR, Resnick S, Magnuson T. Genome-wide transcriptional regulation mediated by biochemically distinct SWI\/SNF complexes. PLOS Genet. 2016;11:e1005748.","journal-title":"PLOS Genet"},{"key":"2944_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109774","volume":"37","author":"F Kuonen","year":"2021","unstructured":"Kuonen F, Li NY, Haensel D, Patel T, Gaddam S, Yerly L, et al. c-FOS drives reversible basal to squamous cell carcinoma transition. Cell Rep. 2021;37:109774.","journal-title":"Cell Rep."},{"key":"2944_CR50","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/s41388-021-01887-2","volume":"40","author":"K-M Launonen","year":"2021","unstructured":"Launonen K-M, Paakinaho V, Sigismondo G, Malinen M, Sironen R, Hartikainen JM, et al. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells. Oncogene. 2021;40:4567\u201379.","journal-title":"Oncogene"},{"key":"2944_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/17460441.2020.1821644","volume":"16","author":"A Hartley","year":"2021","unstructured":"Hartley A, Leung HY, Ahmad I. Targeting the BAF complex in advanced prostate cancer. Expert Opin Drug Discov. 2021;16:173\u201381.","journal-title":"Expert Opin Drug Discov"},{"key":"2944_CR52","doi-asserted-by":"crossref","unstructured":"Arriaga JM, Abate-Shen C. Genetically engineered mouse models of prostate cancer in the postgenomic era. Cold Spring Harb Perspect Med. 2019;1:9.","DOI":"10.1101\/cshperspect.a030528"},{"key":"2944_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34871-9","volume":"13","author":"N Li","year":"2022","unstructured":"Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, et al. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun. 2022;13:7281.","journal-title":"Nat Commun"},{"key":"2944_CR54","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen Y, Kim J, Yang S, Wang H, Wu CJ, Sugimoto H, et al. Type I collagen deletion in \u03b1SMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell. 2021;39:548\u201365.e6.","journal-title":"Cancer Cell"},{"key":"2944_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1172\/JCI123557","volume":"129","author":"Y Ding","year":"2019","unstructured":"Ding Y, Li N, Dong B, Guo W, Wei H, Chen Q, et al. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest. 2019;129:759\u201373.","journal-title":"J Clin Invest"},{"key":"2944_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00856-5","volume":"29","author":"J Mandal","year":"2022","unstructured":"Mandal J, Mandal P, Wang T-L, Shih I-M. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29:71.","journal-title":"J Biomed Sci"},{"key":"2944_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.","journal-title":"Nat Commun"},{"key":"2944_CR58","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1172\/JCI130445","volume":"130","author":"L Wang","year":"2020","unstructured":"Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, et al. Inhibition of the ATM\/Chk2 axis promotes cGAS\/STING signaling in ARID1A-deficient tumors. J Clin Invest. 2020;130:5951\u201366.","journal-title":"J Clin Invest"},{"key":"2944_CR59","doi-asserted-by":"publisher","first-page":"890","DOI":"10.7150\/jca.21306","volume":"9","author":"L Yang","year":"2018","unstructured":"Yang L, Yang G, Ding Y, Dai Y, Xu S, Guo Q, et al. Inhibition of PI3K\/AKT signaling pathway radiosensitizes pancreatic cancer cells with ARID1A deficiency in vitro. J Cancer. 2018;9:890\u2013900.","journal-title":"J Cancer"},{"key":"2944_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54757-z","volume":"9","author":"B Niedermaier","year":"2019","unstructured":"Niedermaier B, Sak A, Zernickel E, Xu S, Groneberg M, Stuschke M. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response. Sci Rep. 2019;9:18207.","journal-title":"Sci Rep."},{"key":"2944_CR61","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","volume":"601","author":"L Xiao","year":"2022","unstructured":"Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, et al. Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601:434\u20139.","journal-title":"Nature"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02944-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02944-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:20:12Z","timestamp":1742311212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02944-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4,6]]}},"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-02944-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.07.597912","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Animal experiments were carried out in line with the revised Animals (Scientific Procedures) Act 1986 and the EU Directive 2010\/63\/EU sanctioned by Local Ethical Review Process (Animals in Science Committee (ASC) Animal Welfare and Ethical Review Body (AWERB) at the University of Glasgow). Mice were maintained on a mixed strain background at the Cancer Research UK Scotland Institute under project licence authority (70\/8645 and P5EE22AEE to Professor Hing Leung). For clinical samples, ethical approval was obtained from the West of Scotland Research Ethics Committee (05\/S0704\/94).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}